Werewolf Therapeutics (HOWL) Accumulated Expenses (2020 - 2026)

Werewolf Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $5.9 million in Q2 2026.

• Accumulated Expenses for Q2 2026 came in at $5.9 million, down 30.66% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.9 million (down 30.66% YoY), and the FY2025 annual result was $5.4 million, down 48.93% from the prior year.
• Accumulated Expenses climbed to $5.9 million in Q2 2026, from $4.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $14.2 million in Q4 2022 and troughed at $4.5 million in Q1 2026.
• A 5-year average of $9.4 million and a median of $8.9 million in 2023 frame the typical range for Accumulated Expenses.
• The widest annual swing landed in 2022, when Accumulated Expenses soared 307.7%; it then slumped 53.34% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $14.2 million in 2022, then tumbled by 37.39% to $8.9 million in 2023, then rose by 19.5% to $10.6 million in 2024, then slumped by 48.93% to $5.4 million in 2025, then grew by 9.56% to $5.9 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $5.9 million in Q2 2026, $4.5 million in Q1 2026, and $5.4 million in Q4 2025.